NEOG · Neogen Corporation · Stock research

Current Thesis

The leg on offer is unchanged from the 2026-07-30 print: a three-year digestion of the acquired 3M Food Safety business finally converting into reported numbers, with a funded deleveraging path attached. Q4 FY26 revenue of $225.3M beat the $212.355M consensus, adjusted EPS of $0.09 landed against a $(0.07) consensus, FY27 revenue was guided to $880–885M versus $849.644M consensus, and the $160M sale of the Genomics unit to Zoetis carries roughly $140M of net proceeds earmarked mainly for debt reduction.

What has moved since the early-August note is flow, not fundamentals. The shares closed at $11.95 on 2026-08-21 after setting a 52-week high of $12.15, having closed $11.47 on 2026-08-07. RSI(14) of 50.8 with price 1.6% under that high describes an advance that stopped extending rather than one being unwound. Over three months the shares are up 34.3%.

The narrative is maturing. The dating: the last analyst target change on the record is Piper Sandler's move to $13 from $11 on 2026-08-03, taken with a Neutral rating retained; in the three weeks since, the only company filing verified for this note is the DEF 14A furnished 2026-08-21 for the 2026-10-01 annual meeting. The prior note put a test in writing — September passing with no new high and no estimates above $13 would force the label down. Half of it has resolved early: the new high arrived but was marginal ($12.15 against the prior $12.04), and no estimate revision followed it. Well known, still working, thinning incremental news.

Bullish and bearish views on Neogen Corporation

The model's bull view on Neogen Corporation (NEOG), in brief: Both lines beat on 2026-07-30: revenue $225.3M vs $212.355M consensus, adjusted EPS $0.09 vs $(0.07) consensus, adjusted EBITDA $45.4M at a 20.2% margin and +12% year over year. The bear view: Growth is still low single digit. FY26 revenue was $870.4M on 1.9% core growth; the FY27 range of $880–885M sits only modestly above it. The equity case rests on margin and balance-sheet repair. The FY27 EBITDA step is small. $180–182M guided against $177.8M delivered in FY26… Both cases follow in full.

Bull Case

• Both lines beat on 2026-07-30: revenue $225.3M vs $212.355M consensus, adjusted EPS $0.09 vs $(0.07) consensus, adjusted EBITDA $45.4M at a 20.2% margin and +12% year over year.
• Food Safety inflected: segment revenue $166.8M on 5.8% core growth, the strongest in three years, with bacteria and general sanitation +10% and indicator testing/culture media +9% (Q4 FY26 presentation, 2026-07-30).
• FY27 guided above the Street on both metrics: $880–885M revenue vs $849.644M consensus; adjusted EBITDA $180–182M. The Q1 FY27 frame is $207–209M vs $204.710M consensus with adjusted EBITDA of roughly $37M.
• The deleveraging path carries dates and dollars: gross debt $794M and cash $186M at 2026-05-31 (net debt $608M); management targets net leverage below 3x by 2026-12-31, funded partly by ~$140M net Genomics proceeds, with completion targeted by the end of FY27's first half on 2026-11-30.
• Cash conversion turned in Q4 FY26: operating cash flow above $30M and free cash flow of $26M, the highest quarterly level of the fiscal year.
• A named margin lever with a number: the Petrifilm manufacturing transition is targeted at 200–300bps of gross margin expansion, against $25M allocated to FY27 transformation work.
• The estimate-cut cycle stopped: Piper Sandler's 2026-08-03 raise to $13 was an upward revision without an upgrade, which is what the end of a de-rating usually looks like before conviction returns.

Bear Case

• Growth is still low single digit. FY26 revenue was $870.4M on 1.9% core growth; the FY27 range of $880–885M sits only modestly above it. The equity case rests on margin and balance-sheet repair.
• The FY27 EBITDA step is small. $180–182M guided against $177.8M delivered in FY26, despite a revenue guide well above consensus — the operating leverage promised by the transformation spend is not yet in the guidance.
• How the mid-year Genomics divestiture is treated inside the FY27 revenue range is not resolvable from the headline release, and it changes the underlying organic comparison a reader would grade the print against.
• The funding source sits with a regulator. The ACCC issued its Phase 2 notice on 2026-07-17, finding the deal would combine the two largest suppliers of cattle genomic testing services in Australia and flagging Zoetis' access to a greater volume and breadth of cattle and sheep genetic data. Submissions closed 2026-07-31. Phase 2 runs up to 90 business days from the notice and the ACCC has published no determination date.
• Price is at the top of the published sell-side range. Piper Sandler's $13 (2026-08-03) is about a dollar above the 2026-08-21 close of $11.95; target aggregators surveyed in mid-August cluster the consensus between $12 and $13, with the compilations disagreeing on the high.
• Adjusted framing throughout. Guidance and margin claims are stated on adjusted EBITDA; GAAP results still carry post-merger integration and transformation charges.

Setup & Price Structure

Reference close 2026-08-21: $11.95, which is 1.6% under the $12.15 52-week high set after 2026-08-07. RSI(14) reads 50.8 — a neutral momentum print at a price a whisker off the high, which is what a flat consolidation after a gap produces. The three-month price change is +34.3%.

The structure carrying the read is the post-print shelf: the 2026-07-30 gap of roughly 10%, then closes of $11.47 (2026-08-07) and $11.95 (2026-08-21) with a marginal new high between them. A weekly close below $11.00 would sit under both of those and hand back the bulk of the gap.

Crowding and positioning observables, stated as observables: no earnings date inside the next 30 days; the last dated sell-side action is 2026-08-03, meaning the marginal new high was made without accompanying estimate revisions; no retail-sentiment clustering was identified in the coverage reviewed for this note; the DEF 14A of 2026-08-21 is a routine annual filing, not issuance. Insider activity is a gap rather than a finding — no Form 4 was verified either way in this review, so it should be treated as unmeasured, not as absence of selling.

Catalyst Calendar (next 30 days)

Through 2026-09-21 the company has nothing scheduled. That is itself the setup condition: a stock up 34.3% in three months, parked 1.6% below its high, with a six-week gap before the next datapoint.

• No scheduled company event before 2026-09-21. The only things that can move the name inside the window are unscheduled: an ACCC procedural step, a deal announcement, or a sell-side revision.
• ~2026-09-21 onward, unscheduled: the ACCC Phase 2 clock has been running since 2026-07-17 and a determination or a timeline extension can be published at any point without notice.
• 2026-10-01 (confirmed, outside the window): annual meeting of shareholders, held virtually; proxy materials were furnished 2026-08-21 covering the election of three Class III directors and the say-on-pay vote.
• ~2026-10-08 (est., outside the window): Q1 FY27 results. Listed as 2026-10-08 by public earnings calendars; the prior-year Q1 was released 2025-10-09.
• ~2026-11-24 (est.): outer edge of the ACCC Phase 2 window, taken as up to 90 business days from the 2026-07-17 notice. No date has been published by the ACCC and the statutory clock can be extended.
• 2026-11-30: end of FY27's first half, management's stated completion window for the $160M Genomics transaction.
• 2026-12-31: management's stated timing for net leverage below 3x.

What Would Change Our Mind

The post-print shelf is what the read is standing on, and losing it is the cleanest break: a weekly close below $11.00 puts the stock under both closes recorded since the 2026-07-30 gap and reframes that print as a single-quarter pop rather than the start of a re-rating.

Beyond price, four fundamental conditions would each do damage on their own: Q1 FY27 revenue printing at or below the $207M low end of management's own guide; Food Safety core growth falling back under 3% from Q4's 5.8%; management dropping or qualifying the "below 3x by end of calendar 2026" language at the Q1 FY27 call; or an ACCC determination that opposes the Zoetis transaction or attaches a structural remedy, which removes the ~$140M of net proceeds behind the leverage target.

The label moves the other way on evidence too. A target revision above $13, or a clean ACCC clearance ahead of the ~2026-11-24 outer window, would restore expanding participation to a name whose news flow has gone quiet, and would argue the maturing call was early. If instead October passes with the Q1 print in line, no target changes and the stock still under $12.15, the honest read drifts toward saturated.

Correlation Notes

• Zoetis is the counterparty, not a comp. The funding leg of this thesis depends on Zoetis' willingness to accept ACCC remedies on an Australian cattle-genomics overlap; Zoetis headlines on that review are a direct input here.
• Food safety and diagnostics peers — Thermo Fisher, Qiagen, Bio-Rad, IDEXX — set the multiple frame, but NEOG's fiscal year ends 31 May, so it reports off-cycle from the group and rarely trades on their prints.
• Levered small-cap sensitivity: net debt of $608M at 2026-05-31 against an equity of this size means credit-spread widening and small-cap risk appetite both transmit into the stock ahead of the paydown.
• Agricultural protein cycle: cattle herd economics drive Animal Safety and genomics volumes; Australian and US cattle market news is the underlying demand series, and the Australian regulatory file overlaps that same market.